U.S. Media Stock News

NasdaqGS:ALGN
NasdaqGS:ALGNMedical Equipment

Align Technology (ALGN) Is Down 5.6% After Earnings Beat And New Buyback - Has The Bull Case Changed?

In late April 2026, Align Technology reported first-quarter sales of US$1,040.09 million and net income of US$112.77 million, beating analyst expectations while reaffirming its full-year 2026 guidance and announcing an additional US$200 million share repurchase under its existing US$1 billion program. At the same time, Align used the AAO 2026 conference to showcase advances across its digital orthodontic platform, including 3D printed attachment systems, enhanced palatal expanders, and...
NasdaqGM:CRSP
NasdaqGM:CRSPBiotechs

Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Approval And CAR T Pipeline Progress

Regulatory approval shifts focus to CRISPR Therapeutics stock CRISPR Therapeutics (CRSP) has moved into the spotlight after securing regulatory approval for its first gene editing therapy, Casgevy, for blood disorders, along with progress in its CAR T pipeline. See our latest analysis for CRISPR Therapeutics. At a share price of US$51.63, CRISPR Therapeutics has seen short term momentum pick up, with a 7 day share price return of 5.83%, while the 1 year total shareholder return of 34.98%...
NYSE:CTS
NYSE:CTSElectronic

What CTS (CTS)'s Strong Q1 Results and Narrowed 2026 Outlook Range Mean For Shareholders

In the first quarter of 2026, CTS Corporation reported higher sales of US$139.23 million and net income of US$17.20 million year over year, and narrowed its full‑year 2026 sales guidance range to US$560 million–US$580 million. Management also reiterated plans to pursue acquisitions to diversify and improve the quality of earnings, signaling continued use of the company’s balance sheet for growth and shareholder returns. Next, we’ll examine how CTS’s stronger quarterly earnings and...
NasdaqGS:DUOL
NasdaqGS:DUOLConsumer Services

Duolingo (DUOL) Is Up 7.5% After Analysts Highlight Another Potential Earnings Beat - What's Changed

In recent days, analysts have highlighted Duolingo, Inc. as having a positive earnings outlook, a history of outperforming estimates, and expectations for quarterly earnings of US$0.79 per share alongside revenue growth of 25.1% year over year. This renewed optimism centers on Duolingo’s ability to convert strong user engagement into higher subscription revenues, supported by consistent earnings surprises that have reinforced confidence in its business model. We’ll now examine how this...
NYSE:MNR
NYSE:MNROil and Gas

Mach Natural Resources (MNR) Is Up 5.7% After Conflicting Q1 EPS Signals Has The Bull Case Changed?

Mach Natural Resources LP is set to report its Q1 2026 earnings on May 7, with analysts expecting lower year-over-year earnings despite higher revenue and a recent sharp upward revision to consensus EPS estimates. This mix of declining earnings expectations, upgraded forecasts, and an Earnings ESP of 0% has heightened uncertainty around the results and management’s commentary, which could be influential for investors following the story. We’ll now examine how this upcoming earnings report,...
NYSE:FCX
NYSE:FCXMetals and Mining

Reassessing Freeport-McMoRan (FCX) Valuation After Morgan Stanley Downgrade And Grasberg Cost Concerns

Morgan Stanley’s downgrade of Freeport-McMoRan (FCX) to Equal Weight, tied to expectations of a slower Grasberg Block Cave ramp-up and higher costs in Indonesia, has become a key pressure point for the stock. See our latest analysis for Freeport-McMoRan. Recent trading has turned weaker, with a 1 day share price return showing a 2.13% decline and a 30 day share price return showing a 7.87% decline. However, the 1 year total shareholder return of 52.15% still signals stronger longer term...
NYSE:ATEN
NYSE:ATENSoftware

Is It Too Late To Consider A10 Networks (ATEN) After Its Strong Multi‑Year Rally?

If you are wondering whether A10 Networks at around US$26.85 is priced attractively or already baking in a lot of optimism, this breakdown is designed to help you frame that question clearly. The stock has seen a 2.6% decline over the last 7 days, alongside returns of 11.9% over 30 days, 54.8% year to date, 65.9% over 1 year, 104.3% over 3 years and 214.4% over 5 years. These movements can change how the market views both its potential and its risks. Recent coverage has focused on A10...
NasdaqGS:CHYM
NasdaqGS:CHYMDiversified Financial

Chime Financial Taps Classroom AI Partnership To Shape Long Term Brand Story

Chime Financial (NasdaqGS:CHYM) has partnered with Junior Achievement USA to roll out AI powered financial literacy programs for students. The partnership includes a redesign of the JA Finance Park program to introduce interactive, experiential money management and career readiness modules. The initiative launches during Financial Literacy Month and focuses on preparing young people for real world financial decisions. For investors tracking Chime Financial, the partnership arrives as the...
NasdaqGM:RZLV
NasdaqGM:RZLVSoftware

Rezolve AI Revolut Listing Expands SQD Reach While Valuation Questions Linger

Rezolve AI's SQD token has been listed on Revolut, expanding access to more than 70 million users worldwide. The listing brings SQD onto a large mainstream fintech platform, beyond crypto focused exchanges. This move is positioned as a step toward mass market adoption of Rezolve AI's decentralized AI commerce infrastructure. Rezolve AI, listed as NasdaqGM:RZLV, is building a decentralized AI commerce infrastructure designed to connect agentic AI systems with real world transactional data...
NasdaqCM:QUBT
NasdaqCM:QUBTTech

Assessing Quantum Computing Inc. (QUBT) Valuation After NeuraWave Deployment Readiness And Conference Spotlight

Quantum Computing (QUBT) is back in focus after confirming that NeuraWave, its photonic reservoir computing platform, is deployment-ready. Management is also preparing to showcase the technology at the upcoming Needham Technology, Media & Consumer Conference. See our latest analysis for Quantum Computing. The NeuraWave update arrives after a sharp 34.06% 1 month share price return, even as the year to date share price return is a 16.35% decline and the 3 year total shareholder return is...
NasdaqGS:AMGN
NasdaqGS:AMGNBiotechs

Did Amgen’s Raised 2026 Outlook and AI-Focused Overhaul Just Shift AMGN’s Investment Narrative?

In the past week, Amgen reported first-quarter 2026 results showing revenue of US$8,618 million and net income of US$1,819 million, with both basic and diluted earnings per share from continuing operations rising year on year, and confirmed it has completed a long-running share repurchase program totaling about US$60.59 billion. Management also raised full-year 2026 revenue guidance and highlighted strong volume growth across key drugs and advancing late-stage candidates, while announcing...
NYSE:SE
NYSE:SEMultiline Retail

Sea (NYSE:SE) Valuation Check As Growth Hopes And Monee Expansion Lift Investor Optimism

Sea (NYSE:SE) is back in focus after recent coverage highlighted expectations for strong earnings and revenue growth ahead of its May 12 report, with fintech arm Monee emerging as a key operational driver. See our latest analysis for Sea. Sea’s recent 1 day share price return of 1.56% and 1 month share price return of 4.76% sit against a weaker backdrop, with a 90 day share price return of a 24.11% decline and a 1 year total shareholder return of a 39.2% decline. This suggests recent momentum...
NYSE:PRA
NYSE:PRAInsurance

Assessing ProAssurance (PRA) Valuation After Recent Steady Trading And Modest Shareholder Returns

How ProAssurance stock has been performing ProAssurance (PRA) has drawn investor interest after relatively steady recent trading. The share price is near US$24.66, with returns of about 0% over the past week and month, and 1% over the past 3 months. See our latest analysis for ProAssurance. Over a longer horizon, ProAssurance’s 7.22% 1 year total shareholder return and 33.95% 3 year total shareholder return point to gradually building momentum beyond the recent, relatively muted share price...
NasdaqGS:ADPT
NasdaqGS:ADPTLife Sciences

Assessing Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness

What recent performance says about Adaptive Biotechnologies Adaptive Biotechnologies (ADPT) has drawn fresh attention after a mixed stretch in the stock, with a slight gain over the past week, a small decline over the past month, and a sharper pullback over the past 3 months. See our latest analysis for Adaptive Biotechnologies. At a share price of $14.27, Adaptive Biotechnologies has had a weak stretch in recent months, with a 30 day share price return of a 3.65% decline and a 90 day share...
NYSE:WU
NYSE:WUDiversified Financial

Western Union’s USDPT Stablecoin Launch and Consumer Services Expansion Could Be A Game Changer For WU

In late April 2026, Western Union reported first-quarter 2026 results with revenue of US$982.7 million and net income of US$64.7 million, and outlined plans to launch its USDPT dollar-backed stablecoin on the Solana blockchain alongside continued expansion in its Consumer Services segment. This combination of a blockchain-based settlement initiative and growing travel money and bill payment activities highlights Western Union’s push to modernize its remittance model and broaden its revenue...
NasdaqGS:ERAS
NasdaqGS:ERASBiotechs

Erasca Confronts Trial Fatality And Lawsuit As Valuation Debate Deepens

Erasca (NasdaqGS:ERAS) disclosed a patient death in its Phase 1 ERAS-0015 trial, triggering heightened safety and regulatory scrutiny. Revolution Medicines filed a patent infringement lawsuit against Erasca, also challenging the way ERAS-0015 has been compared to its own programs. These events follow a recent preliminary positive data update for ERAS-0015 and introduce fresh uncertainty around the asset and broader pipeline. Erasca comes into this twin shock with a share price of $10.03 and...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Is It Time To Reassess Madrigal Pharmaceuticals (MDGL) After Its Strong Five Year Share Price Gain

If you are trying to figure out whether Madrigal Pharmaceuticals is priced attractively today, the starting point is understanding what the current share price really reflects. The stock most recently closed at US$513.72, with returns of 0.3% over 7 days, a 6.1% decline over 30 days, a 13.5% decline year to date, a 62.8% return over 1 year, a 67.7% return over 3 years, and a very large 5 year gain of 293.9%. These mixed short term and longer term moves have kept Madrigal on the radar of...
NYSE:TOST
NYSE:TOSTDiversified Financial

A Look At Toast’s (TOST) Valuation After The Toast Go 3 International Launch

Why Toast’s Toast Go 3 launch is attracting fresh investor attention Toast (TOST) has drawn fresh interest after launching its Toast Go 3 handheld point of sale device across the UK, Ireland, Canada, and Australia, expanding its hardware footprint beyond its core US restaurant base. The rollout introduces a purpose built terminal with cellular and Wi Fi connectivity, long battery life, and tools that support menu upsells and personalized service. This gives investors a concrete development to...
NYSE:VOYA
NYSE:VOYADiversified Financial

Weighing Voya Financial (VOYA) Valuation As Policy Support And $1t Assets Fuel Investor Optimism

Voya Financial (VOYA) is in focus after publicly supporting a recent executive order aimed at broadening access to private sector IRAs, while also reporting more than $1 trillion in assets and nearly 10 million participant accounts. See our latest analysis for Voya Financial. The recent 22.95% 1 month share price return, together with a 38.83% 1 year total shareholder return, suggests momentum has been building as investors respond to policy support, dividend affirmations, and Voya’s $1t...
NYSE:SEI
NYSE:SEIEnergy Services

A Look At Solaris Energy Infrastructure (SEI) Valuation After Strong Q1 Results And Expanded Long Term Power Contracts

Solaris Energy Infrastructure (SEI) is back in focus after first quarter 2026 results showed higher sales, revenue, and net income versus a year earlier, along with raised earnings guidance and expanded long term power contracts. See our latest analysis for Solaris Energy Infrastructure. SEI shares have cooled slightly after recent highs, with a 1 day share price return of 2.04% and a relatively flat 7 day move. However, the 30 day share price return of 29.62% and year to date gain of 43.91%...
NYSE:RBLX
NYSE:RBLXEntertainment

Roblox (RBLX) Is Down 19.5% After Cutting Guidance Amid New Safety Rules – Has The Bull Case Changed?

In the past week, Roblox reported Q1 2026 results showing sales rising to US$1,442 million from US$1,035 million a year earlier, while net loss widened to US$246 million and management cut full‑year revenue and bookings guidance due to new child‑safety measures and age‑verification rules. These safety and compliance changes, which restricted communication and slowed new user acquisition, underline Roblox’s decision to prioritize platform integrity even as they weigh on near‑term growth...
NasdaqGS:ANAB
NasdaqGS:ANABBiotechs

Assessing AnaptysBio’s Valuation After Strong Recent Share Price Momentum

Why AnaptysBio is on investors’ radar AnaptysBio (ANAB) has attracted attention after a recent share price move, with the stock showing double digit returns over the past week, month and past 3 months. This performance is prompting some investors to reassess its profile. See our latest analysis for AnaptysBio. Beyond the recent surge, the momentum in AnaptysBio’s share price return has been building for some time, and the very large 1 year total shareholder return suggests investors have been...
NYSE:JBL
NYSE:JBLElectronic

Assessing Jabil (JBL) Valuation After New Sivers Partnership Targets Greener AI Data Centers

Jabil (JBL) recently drew attention after partnering with Sivers Semiconductors to develop a 1.6T linear receive optical transceiver, which is aimed at reducing energy use in next generation AI data centers. See our latest analysis for Jabil. The recent 1.6T optical transceiver partnership comes on top of strong momentum, with a 30 day share price return of 27.53% and a 90 day share price return of 40.81%, while the 1 year total shareholder return of 128.12% points to a very large gain over a...
NasdaqGM:ADMA
NasdaqGM:ADMABiotechs

ADMA Biologics (ADMA) Is Down 6.6% After Fraud Allegations and Probe Escalate - What's Changed

In recent weeks, ADMA Biologics has come under scrutiny after a Culper Research short-seller report alleging channel stuffing and an undisclosed related-party distributor prompted a securities-fraud investigation by law firm Pomerantz and an analyst downgrade. At the same time, ADMA is preparing to release its first-quarter 2026 results and host a management webcast, meaning investors will soon hear the company’s formal response to these allegations and its broader business outlook...